Opendata, web and dolomites

BADGER SIGNED

CalScreener® – an innovative device for Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BADGER project word cloud

Explore the words cloud of the BADGER project. It provides you a very rough idea of what is the project "BADGER" about.

clinical    sold    efficient    packaged    paradigm    resistant    speed    segment    validating    first    bioenergetics    clinicians    cellular    stewardship    micro    correct    pharmaceutical    date    patient    suitable    smartly    redefine    assay    causing    meet    hetero    contributes    ill    device    cell    calorimetric    near    prescribing    vitro    combat    gt    inappropriate    symcel    tool    foundation    accuracy    personalized    lay    amr    treatment    introduce    validate    patients    perform    settings    break    antibiotics    ast    readily    diagnostic    extensively    broad    lack    mic    time    clinically    overuse    misuse    provides    assays    though    multichannel    specificity    intend    pure    setting    isothermal    infections    calscreenertm    accurate    commercializing    critically    sepsis    healthcare    combination    rapid    antibiotic    designed    susceptibility    resistance    daily    calorimetry    diagnoses    badger    antimicrobial    commercial    diagnostics    sensitivity    line    service    strains    decisions    tools    solution   

Project "BADGER" data sheet

The following table provides information about the project.

Coordinator
SYMCEL AB 

Organization address
address: DOMNARVSGATAN 4
city: SPANGA
postcode: 163 53
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://symcel.com/h2020-ast-combination-testing/
 Total cost 3˙572˙567 €
 EC max contribution 3˙572˙567 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYMCEL AB SE (SPANGA) coordinator 3˙572˙567.00

Map

 Project objective

SymCel provides a novel cell-based assay tool for real-time cellular bioenergetics measurements. Our key product, the calScreenerTM, is the first multichannel calorimetric system specifically developed for cell-based assays, which to date has been sold to the pharmaceutical research segment only. Even though calorimetry is a highly advanced research tool, it is considered not suitable for broad scale uptake into daily clinical practice. Through the BADGER project we intend to break this paradigm by validating and commercializing an in vitro diagnostic tool, that is based on isothermal micro calorimetry, for determining MIC for antimicrobial susceptibility testing (AST) of hetero-resistant sepsis causing strains. By providing a tool for the easy, correct and timely diagnoses of hetero-resistant and extensively resistant infections, we will redefine the commercial application segment for calorimetry systems (from pure research settings -> near patient diagnostics) and take AST to a new level of accuracy and speed. The clinical importance of AST is increasing in line with the growing concerns over antimicrobial-resistance (AMR) and the misuse of antibiotics. Lack of a rapid, low-cost and readily available solution contributes to the inappropriate prescribing and overuse of antibiotics. Clinicians are in need of an accurate and rapid diagnostic test to increase antibiotic stewardship, introduce combination treatment for critically ill patients and help combat AMR. The calScreenerTM will meet the users’ needs by providing a reliable diagnostic tool with high speed, specificity, and sensitivity in a smartly designed and packaged device with the tools available to perform testing in a near-patient setting. In all, the Phase 2 project will lay the foundation to clinically validate the calScreenerTM which will improve diagnostic decisions, provide a higher service level for patients, combat AMR and allow for more personalized and cost-efficient approaches to healthcare.

 Deliverables

List of deliverables.
Project subpage on corporate website Websites, patent fillings, videos etc. 2020-03-04 09:46:23
Ethics approval for Clinical study no. 2 Documents, reports 2020-03-04 09:46:23
Ethics approval for Clinical study no. 1 Documents, reports 2020-03-04 09:46:23
Ethics approval for Clinical study no. 3 Documents, reports 2020-03-04 09:46:23

Take a look to the deliverables list in detail:  detailed list of BADGER deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BADGER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BADGER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

SHIGETECVAX (2019)

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Read More